A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2029-12-09
Target enrollment:
Participant gender:
Summary
This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.